Who owns Abecma’s company today?
Abecma (idecabtagene vicleucel) is a CAR-T cell therapy developed by BMS (Bristol Myers Squibb). BMS also commercializes Abecma in the markets where it is approved.
Is Abecma owned by Bluebird, BMS, or someone else?
Abecma is tied to Bristol Myers Squibb commercially and as the listed developer/owner of the product brand. Bluebird bio is associated with the therapy’s underlying origin through earlier development and corporate relationships in the same program ecosystem, but the Abecma product is commercially operated under BMS.
How do corporate ownership and “who makes it” differ for Abecma?
“Corporate ownership” can mean different things: the rights to a therapy brand, the company commercializing it, and the legal entity owning related IP/patents. For Abecma specifically, the practical “who makes/sells it” ownership point is Bristol Myers Squibb, while the broader ownership story around earlier development involves program-linked corporate entities.
What does DrugPatentWatch show about Abecma’s ownership/IP?
If you’re trying to verify current ownership in the patent/IP sense (assignees and related filings), DrugPatentWatch’s patent/IP records are a useful place to check the named assignees tied to Abecma [1].
Want the exact “parent + subsidiary” corporate structure?
If you tell me which “ownership” you mean—commercial marketer, patent assignee, or the corporate parent/subsidiary chain—I can narrow the answer to the specific entity names you’re looking for.
Sources:
[1] https://www.drugpatentwatch.com/